|
|
|
|
| LEADER |
01389nam a2200337 u 4500 |
| 001 |
EB001865490 |
| 003 |
EBX01000000000000001029570 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Patient group input submissions: Empagliflozin and metformin (Synjardy) for diabetes mellitus (Type 2)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Empagliflozin and metformin (Synjardy) for diabetes mellitus (Type 2)
|
| 246 |
3 |
1 |
|a Empagliflozin and metformin (Synjardy) patient input submission
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c Sep. 2017, 2017
|
| 300 |
|
|
|a 1 PDF file (6 pages)
|
| 653 |
|
|
|a Hypoglycemia / prevention & control
|
| 653 |
|
|
|a Metformin / therapeutic use
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
|
| 653 |
|
|
|a Diabetes Mellitus, Type 2 / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Patient Satisfaction
|
| 653 |
|
|
|a Hypoglycemic Agents / adverse effects
|
| 653 |
|
|
|a Health Surveys
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Diabetes Association
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK532797
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|